Search results
Results from the WOW.Com Content Network
John McMillan Mennell testified in favor of chiropractic. Even the defendants' economic witness, Mr. Lynk, assumed that chiropractors outperformed medical physicians in the treatment of certain conditions and he believed that was a reasonable assumption. The defendants have offered some evidence as to the unscientific nature of chiropractic.
Chiropractic constitutes a hazard to rational health care in the United States because of its substandard and unscientific education of its practitioners and their rigid adherence to an irrational, unscientific approach to disease causation. The longstanding feud between chiropractors and medical doctors continued for decades.
For premium support please call: 800-290-4726 more ways to reach us
The demand for healthcare is a derived demand from the demand for health. Healthcare is demanded as a means for consumers to achieve a larger stock of "health capital". The demand for health is unlike most other goods because individuals allocate resources in order to both consume and produce health. [citation needed]
A chiropractor may have a Doctor of Chiropractic (D.C.) degree and be referred to as "doctor" but is not a Doctor of Medicine (M.D.) or a Doctor of Osteopathic Medicine (D.O.). [5] [6] While many chiropractors view themselves as primary care providers, [7] [8] chiropractic clinical training does not meet the requirements for that designation. [2]
The 1.5 mg and 4.5 mg doses of Trulicity, another diabetes drug by Lilly, will also be available in limited amounts through April due to increased demand, according to the FDA's website.
Concerns of both a current and future shortage of medical doctors due to the supply and demand for physicians in the United States have come from multiple entities including professional bodies such as the American Medical Association (AMA). [1] The AMA itself has been criticized for creating the shortage in the first place. [2]
The popular diabetes treatment Mounjaro pushed Eli Lilly past fourth-quarter forecasts, and the drugmaker predicted that 2024 will turn out largely better than expected too as new products build ...